Pfizer, Astellas report positive results from trial of Xtandi in non-metastatic castration-resistant disease

Combination immunotherapy + chemo is safe and effective for advanced small cell cancers in bladder and prostate

A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve treatment outcomes for patients with small cell bladder cancer and small cell/neuroendocrine prostate cancer.

November 15, 2024

Vol.50 No.43

Clinical Trials & Tribulations

A study measures the long-term downside of prostate cancer screening
A paper in JAMA Oncology focuses on the harms of overscreening, overdiagnosis, and overtreatment

In this week’s issue of JAMA Oncology, there is an important paper that provides information concerning the long-term adverse effects and complications of prostate cancer screening and treatment. xxx:more

Long-term risks from prostate cancer treatment detailed in new report

A new report says those considering PSA screening need such quantitative information on risks and benefits of treatment if they are to make truly informed decisions. Yet leading guidelines do not provide specific estimates of risk. The risks of adverse effects and complications from treatment for prostate cancer are substantial and continue for years after...

November 08, 2024

Vol.50 No.42

Clinical Roundup

AI may be more accurate vs. traditional methods at classifying patients into prostate cancer risk groups

For localized prostate cancer, multimodal artificial intelligence models have revealed a more accurate way to assess prostate cancer risk. By combining advanced artificial intelligence with digital pathology images and clinical data, researchers developed a way to approach risk classification that outperforms traditional methods. These findings were published in JCO Precision Oncology. The research found that...

November 08, 2024

Vol.50 No.42

In Brief

UCLA Urology awarded $6M from CA Department of Health Care Services to serve vulnerable patients with prostate cancer

UCLA’s urology department was awarded $6 million from the California Department of Health Care Services to continue providing care and critical services to underinsured and uninsured Californians diagnosed with prostate cancer.

October 25, 2024

Vol.50 No.40

In Brief

UCLA’s Luca Valle receives $2.1M grant from VA to improve prediction of radiorecurrent prostate cancer outcomes

Luca Valle, assistant professor of radiation oncology at the David Geffen School of Medicine at UCLA, was awarded a $2.1 million grant from the U.S. Department of Veterans Affairs to develop new methods to better understand the clinical scope and biological factors that lead to prostate cancer coming back after radiation therapy.

October 25, 2024

Vol.50 No.40

Pfizer, Astellas report positive results from trial of Xtandi in non-metastatic castration-resistant disease

YOU MAY BE INTERESTED IN

Combination immunotherapy + chemo is safe and effective for advanced small cell cancers in bladder and prostate

A study measures the long-term downside of prostate cancer screening
A paper in JAMA Oncology focuses on the harms of overscreening, overdiagnosis, and overtreatment

Long-term risks from prostate cancer treatment detailed in new report

AI may be more accurate vs. traditional methods at classifying patients into prostate cancer risk groups

UCLA Urology awarded $6M from CA Department of Health Care Services to serve vulnerable patients with prostate cancer

UCLA’s Luca Valle receives $2.1M grant from VA to improve prediction of radiorecurrent prostate cancer outcomes

Renew today!

Subscriber content

Never miss an issue!

Login

Pfizer, Astellas report positive results from trial of Xtandi in non-metastatic castration-resistant disease

YOU MAY BE INTERESTED IN

Combination immunotherapy + chemo is safe and effective for advanced small cell cancers in bladder and prostate

A study measures the long-term downside of prostate cancer screeningA paper in JAMA Oncology focuses on the harms of overscreening, overdiagnosis, and overtreatment

Long-term risks from prostate cancer treatment detailed in new report

AI may be more accurate vs. traditional methods at classifying patients into prostate cancer risk groups

UCLA Urology awarded $6M from CA Department of Health Care Services to serve vulnerable patients with prostate cancer

UCLA’s Luca Valle receives $2.1M grant from VA to improve prediction of radiorecurrent prostate cancer outcomes

Never miss an issue!

Login

A study measures the long-term downside of prostate cancer screening
A paper in JAMA Oncology focuses on the harms of overscreening, overdiagnosis, and overtreatment